
Meusinvest, Spinventure in €4m round for PDC Line Pharma
Belgian VC Meusinvest and Spinventure have contributed to a €4m series-A round for biotechnology company PDC Line Pharma, specialised in cancer immunotherapy technology.
The round was led by Meusinvest and institutional investor Financière Spin-off Luxembourgeoise, managed by Investsud Group. According to a source close to the deal, other investors in the round included family offices, which provided around half of the capital.
The round featured €2.6m of equity, and €1.4m in bank loans, EU funding and investment from Belgian and French regional funds Walloon Region, Wallonia Biotech Coaching and Auvergne-Rhône Alpes Initiative.
Entrepreneur Eric Halioua will join the company (led by COO Laurent Levy and CSO Joel Plumas) as CEO and president of the board of directors. Halioua will also be in charge of PDC Line Pharma's fundraising efforts.
Halioua told unquote" PDC Line Pharma will be looking for extra funding of between €13-20m in the coming years, in order to further fund clinical testing.
The current round of funding is intended to finance the company's next 12-18 months of activity, allowing its cancer immunotherapy technology to reach the clinical proof of concept phase. This clinical trial is nearing completion, the company said, with results expected in Q2 2017. PDC Line Pharma will also finalise the industrialisation of its process and investigate the potential applications of its technology.
Other objectives include team expansion, with plans to double up the group's workforce and reach 18 people by the end of 2017.
Previous funding
According to a company statement, PDC Line Pharma has benefited from the support of several partners, including BPI France, Auvergne-Rhône-Alps Initiative, EFS (French Blood Bank), the European commission, the French ministry of research, and various incubators. However, the series-A is the first formal round of institutional funding the company has raised.
Company
PDC Line Pharma was founded in 2014 in Grenoble as a spinout from the French Blood Bank (EFS).
The clinical-stage biotech company develops antigen-specific active immunotherapies for cancer based on a plasmacytoid dendritic cell (PDC) line.
People
Meusinvest Group – Marc Foidart (deputy CEO).
PDC Line Pharma – Eric Houlia (CEO).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater